[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postsurgical-pain-management\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postsurgical-pain-management":84},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,59],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053401",false,"NCT07296770","An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service","TPS-Select","Patients may take part in this study if they:\n\n* Are 18 years or older\n* Are having a planned (elective) surgery at UCSF\n* Are identified as higher risk for chronic pain after surgery by a computer model\n* Agree to join the study and sign consent\n\nPatients cannot take part if they:\n\n* Have too much missing information in their medical record (more than 75%)\n* Have a surgery scheduled less than 1 month away\n* Have serious memory or thinking problems that make participation difficult\n* Are in another clinical study that would interfere with this one\n* Do not live in California\n* Choose not to participate or sign consent\n* Have severe depression with suicidal thoughts that requires urgent care\n* Are pregnant or breastfeeding\n\nA patient who has already joined may be removed from the study if they:\n\n* Cannot complete most of the scheduled follow-up phone calls or pre-surgery recommendations (up to 6 months after discharge)\n* Pass away between the surgery booking date and 6 months after leaving the hospital\n* Become pregnant in the 6 months after discharge\n\nPatients may remain enrolled but their data may not be used in the main study results if they experience:\n\n* A long-lasting infection after surgery\n* Hardware problems related to their surgery (for example, issues with implanted devices)\n* A major injury or life event that affects their pain levels, such as a significant fall or an emergency surgery\n* Difficulty completing the planned follow-up phone calls up to 6 months after discharge","ALL","18 Years",{"count":18,"type":19},126,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","The goal of this clinical trial is to learn whether a pain-management program called a Transitional Pain Service can help prevent long-term pain and reduce opioid needs after surgery in adult surgical patients who may be at higher risk for developing persistent pain. The main questions this trial aims to answer are: 1) Does the Transitional Pain Service help high-risk surgical patients manage pain better after surgery? 2) Can a computer tool (an algorithm) improve screening of patients for long-lasting pain after surgery? The investigators will compare patients who continue with their usual care to patients who receive support from the Transitional Pain Service to see if the program leads to better pain control and lower opioid use. Participants will share information about their pain levels and the pain-relief treatments they are using before and after surgery so researchers can better understand how the program affects recovery. Patients assigned to the Transitional Pain Service will also be offered additional coordinated support before and after their surgery to help optimize their pain control and overall recovery.",[25,26,27],"Postsurgical Pain Management","Postsurgical Pain, Chronic","Opioid Use After Surgery",[29,30,31,32],"Pain","Transitional Pain Service","Postsurgical Pain","Postoperative Opioid Use","NOT_YET_RECRUITING","2026-07-09",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":19},"2026-10-01",{"date":41,"type":19},"2028-07-01",{"name":43,"class":44},"University of California, San Francisco","OTHER",1,{"id":47,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":20,"phases":49,"briefSummary":23,"conditions":50,"keywords":51,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":58,"locationsCount":45},"100615758",{"count":18,"type":19},[22],[25,26,27],[29,30,31,32],"2025-12-18",{"date":54,"type":37},"2025-12-22",{"date":56,"type":19},"2026-05-01",{"date":41,"type":19},{"name":43,"class":44},{"id":60,"slug":4,"hasResults":10,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":20,"phases":68,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100560217","NCT06574269","A Study on TLC590 for Managing Postsurgical Pain","A Phase 2, Open-label, Dose-escalation Study to Evaluate Pharmacokinetics, Pharmacodynamics, Bioavailability, Safety, and Tolerability of TLC590 in Multiple Surgical Models","Inclusion Criteria:\n\n1. Able and willing to provide written informed consent\n2. Male or female aged 18 to 70 years, inclusive. For the Part 2 breast augmentation surgical model, only females can be enrolled\n3. Scheduled to undergo one of the following elective surgeries, with no additional procedures and be able to use the anesthesia regimen:\n\n   1. Unilateral first metatarsal bunionectomy (Cohort 1)\n   2. Laparoscopy-assisted open ventral hernia repair (Cohort 2 and 6)\n   3. Breast augmentation (Cohort 3 through 5)\n   4. Unilateral total knee arthroplasty (Cohort 7)\n   5. Abdominoplasty (tummy tuck) (Cohort 8)\n4. ASA Physical Status Classification of 1 or 2\n5. Male subjects must be either biologically or surgically sterile or commit to the use of a reliable method of birth control (must agree to use double-barrier contraception in the event of sexual activity) or be practicing abstinence for the duration of the study and for 30 days after study drug administration\n6. Female subjects are eligible only if all the following apply:\n\n   1. Not pregnant with a negative serum pregnancy test at Screening and negative urine pregnancy test on Day 1 before surgery (pregnancy test not required for females of non-childbearing potential, defined as surgically sterile or post-menopausal)\n   2. Not lactating\n   3. Not planning to become pregnant during the study\n   4. If of childbearing potential, commits to the use of a highly effective method of birth control for the duration of the study and or at least 30 days after study drug administration\n7. BMI \\>18 \\~ ≤39 kg\u002Fm2\n\nExclusion Criteria:\n\n1. A clinically significant abnormal clinical laboratory test value\n2. Evidence of a clinically significant 12-lead ECG\n3. History of orthostatic hypotension, syncope, or other syncopal attacks\n4. History or any clinical manifestation of significant renal, hepatic, gastrointestinal, cardiovascular, metabolic, neurologic, psychiatric, or other condition that has been assessed by the Investigator to be unsuitable for participation in the study\n5. History of seizures or taking anticonvulsants during the Screening period\n6. History of cardiac arrhythmia or taking Class III antiarrhythmic drugs including amiodarone, dofetilide, dronedarone, sotalol, or ibutilide during the Screening period\n7. History of sleep apnea or on home CPAP treatment\n8. History of hypersensitivity to ropivacaine, any other amide-type local anesthetic, propofol, hydromorphone, fentanyl, midazolam, acetaminophen, oxycodone, or morphine (or other opioids)\n9. History of severe or refractory PONV due to other etiologies, including, but not limited to gastric outlet obstruction, hypercalcemia, or active peptic ulcer, deemed clinically significant by the Investigator\n10. Any lifetime history of a suicidal attempt or any suicidal behavior, as assessed by the C-SSRS at Screening\n11. History or positive test results of HIV, HCV, or HBV\n12. History or current report of substance abuse including illicit drug abuse and\u002For alcohol abuse (regularly drinks \\>4 units of alcohol per day: 1 unit = 8 oz. beer, 3 oz. wine, or 1 oz. spirits) within 2 years prior to Screening\n13. Positive results on the urine drug screen or alcohol breath test indicative of illicit drug or non-prescribed drug or alcohol abuse at Screening or on Day 1 before surgery. Prescribed medication that is known to result in a positive drug test is allowed. Marijuana (medical or recreational) is not allowed\n14. Pre-existing concurrent acute, or chronic painful restrictive\u002Fphysical condition that may confound postoperative pain assessments or is expected to require analgesic treatment during the study\n15. Has known or suspected daily use of opioids for longer than 4 days per week within the previous 6 months prior to Screening\n16. Is taking daily analgesics for longer than 4 days per week for a chronically painful condition during the Screening period. Not exclusionary if it is utilized for pain related to the total knee arthroplasty indication\n17. Is receiving oxygen therapy during the Screening period\n18. Use of any of the following medications within 5 half-lives prior to the study surgical procedure or as specified\n19. Malignancy in the last 2 years prior to Screening, except for non-metastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix\n20. Personal or family history of malignant hyperthermia","70 Years",{"count":67,"type":19},120,[69],"PHASE2","This Phase 2 open-label trial investigates the pharmacokinetics (PK), pharmacodynamics, and safety profile of TLC590 across various surgical procedures. Researchers aim to determine the maximum tolerated dose (MTD) of TLC590 via Safety Monitoring Committee (SMC).\n\nThe study evaluates TLC590 in bunionectomy, laparoscopy-assisted open ventral hernia repair, breast augmentation, abdominoplasty, and total knee arthroplasty models. Additionally, it determines the relative bioavailability of TLC590 to ropivacaine injection.",[25],"RECRUITING","2025-11-24",{"date":75,"type":37},"2025-12-02",{"date":77,"type":37},"2024-09-30",{"date":79,"type":19},"2026-08",{"name":81,"class":82},"TLC Biopharmaceuticals, Inc.","INDUSTRY",2,""]